6,8-Disubstituted purine derivatives of 9-.beta.-D-ribofuranosyl 3',5'-cyclic phosphate
US4058659A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Sep 29, 1975 |
| Grant date | Nov 15, 1977 |
| Priority date | — |
| Expiry date | Sep 29, 1995 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/20
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds of formula ##STR1## wherein X is --NR.sub.1 R.sub.2, --Cl, --Br or SR; Y is --X, --OH or --NH.sub.2 ; Z is hydrogen or --NH.sub.2 ; and R' is hydrogen or C.sub.1 -C.sub.18 acyl; R being hydrogen, aryl, aralkyl, substituted aryl, substituted aralkyl, or C.sub.1 -C.sub.7 alkyl; and R.sub.1 and R.sub.2 being independently selected from the group consisting of hydrogen, phenyl, C.sub.7 -C.sub.10 aralkyl, C.sub.1 -C.sub.7 alkyl, C.sub.1 -C.sub.10 branched chain alkyl, C.sub.1 -C.sub.7 unsaturated alkyl or lower alkyl joined to form a 5 or 6-membered heterocyclic ring, with the proviso that when one of R.sub.1 and R.sub.2 are hydrogen, the other is not. The compounds variously exhibit phosphodiesterase inhibition, protein kinase activation, positive inotropic effects, adenyl cyclase inhibition and other biological activities.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.